STERIS plc $STE Shares Sold by Krilogy Financial LLC

Krilogy Financial LLC cut its stake in STERIS plc (NYSE:STE) by 65.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,752 shares of the medical equipment provider’s stock after selling 3,350 shares during the quarter. Krilogy Financial LLC’s holdings in STERIS were worth $385,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its stake in shares of STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after buying an additional 349 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in STERIS by 32.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after acquiring an additional 59,264 shares in the last quarter. Empowered Funds LLC raised its holdings in STERIS by 16.1% in the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 319 shares during the last quarter. Woodline Partners LP raised its holdings in STERIS by 40.0% in the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after acquiring an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after purchasing an additional 5,803 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Stock Performance

NYSE STE opened at $215.59 on Monday. The stock has a fifty day simple moving average of $212.77 and a 200-day simple moving average of $233.10. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market cap of $21.01 billion, a PE ratio of 27.19 and a beta of 0.93. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Equities analysts anticipate that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Analyst Ratings Changes

STE has been the subject of a number of analyst reports. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. KeyCorp reduced their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $278.00.

Insider Buying and Selling

In other STERIS news, VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president directly owned 35,259 shares in the company, valued at $7,379,003.52. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the transaction, the director owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 7,328 shares of company stock valued at $1,554,051. Company insiders own 1.12% of the company’s stock.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.